Iterum Therapeutics plc (ITRMF) Cash from Investing Activities (2017 - 2025)

Iterum Therapeutics has reported Cash from Investing Activities for 9 years, with the latest figure at -$12000.0 in Q3 2025.

• On a quarterly basis, Cash from Investing Activities fell 100.21% year-over-year to -$12000.0 in Q3 2025; TTM through Sep 2025 was $1.1 million, a 96.45% decrease from a year earlier, with the FY2024 full-year figure at $18.2 million, down 21.97% from the prior year.
• Cash from Investing Activities was -$12000.0 for Q3 2025 at Iterum Therapeutics, down from -$2000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $13.5 million in Q4 2023, with the low at -$33.9 million in Q1 2021.
• Average Cash from Investing Activities over 5 years is $49555.6, with a median of $3.8 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2025: Cash from Investing Activities soared 54933.33% in 2021, then sank 100.21% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$4.5 million in 2021, then jumped by 198.03% to $4.4 million in 2022, then surged by 208.89% to $13.5 million in 2023, then sank by 91.87% to $1.1 million in 2024, then slumped by 101.09% to -$12000.0 in 2025.
• The last three Cash from Investing Activities figures came in at -$12000.0 (Q3 2025), -$2000.0 (Q1 2025), and $1.1 million (Q4 2024), per Business Quant data.